Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eplerenone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 known ✓ | P08235 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eplerenone SCHEMBL14567750 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14567731 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14284960 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL16144481 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL1818157 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL13061287 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14308852 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL13007056 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL21515 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL19891818 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160175328-A1 | COMPOSITIONS AND TREATMENTS OF HEART FAILURE IN NON-HUMAN MAMMAL ANIMALS | CEVA SANTE ANIMALE SA (FR) | 2016-06-23 | — | — | US | disclosed |
| US-20160175328-A1 | COMPOSITIONS AND TREATMENTS OF HEART FAILURE IN NON-HUMAN MAMMAL ANIMALS | CEVA SANTE ANIMALE SA (FR) | 2016-06-23 | — | — | US | disclosed |
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100183718-A1 | COMPOSITIONS AND TREATMENT OF HEART DEFICIENCY IN NON-HUMAN ANIMALS | CEVA SANTE ANIMALE SA (FR) | 2010-07-22 | — | — | US | disclosed |
| US-20100183718-A1 | COMPOSITIONS AND TREATMENT OF HEART DEFICIENCY IN NON-HUMAN ANIMALS | CEVA SANTE ANIMALE SA (FR) | 2010-07-22 | — | — | US | disclosed |
| US-20090270356-A1 | COMPOSITIONS AND TREATMENTS OF HEART FAILURE IN NON-HUMAN MAMMAL ANIMALS | CEVA SANTE ANIMALE SA (FR) | 2009-10-29 | — | — | US | disclosed |
| US-20090270356-A1 | COMPOSITIONS AND TREATMENTS OF HEART FAILURE IN NON-HUMAN MAMMAL ANIMALS | CEVA SANTE ANIMALE SA (FR) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175328-A1 | COMPOSITIONS AND TREATMENTS OF HEART FAILURE IN NON-HUMAN MAMMAL ANIMALS | NPPA, REN, NR3C2 | NR3C2 3/4885NR3C1 38/4885PGR 528/4885 |
| US-20100183718-A1 | COMPOSITIONS AND TREATMENT OF HEART DEFICIENCY IN NON-HUMAN ANIMALS | TNNI3, TNNT2, TNNC1 | NR3C2 5/4885NR3C1 162/4885PGR 1984/4885 |
| US-20090270356-A1 | COMPOSITIONS AND TREATMENTS OF HEART FAILURE IN NON-HUMAN MAMMAL ANIMALS | NPPA, REN, NR3C2 | NR3C2 3/4885NR3C1 38/4885PGR 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.